235 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 5 of 5
Condition: Transplant
Investigator: David Lederer, MD
Status: Closed
The purpose of this study is to detect Bronchiolitis Obliterans Syndrome (BOS) at an early stage. Bronchiolitis Obliterans (BOS) is a form of chronic lung transplant dysfunction that affects many lung transplant recipients and can limit long-term survival. This study aims to increase the success…
Condition: Transplant
Investigator: Selim Arcasoy, MD
Status: Closed
This study is for patients who have had a lung transplant and whose doctors believe that their body is rejecting the new lung, resulting in damage to the transplanted lung or lungs. This condition is called Bronchiolitis Obliterans…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Meyer Kattan, MD
Status: Currently Recruiting
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
This study is designed to examine the efficacy and safety profile of dupilumab over one year in a population of asthmatic children in need for an additional treatment to their current maintenance management. Patients are randomized to either dupilumab or matching placebo administered standard care for a maximum treatment duration of 52 weeks. The…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Joyce Yu, MD
Status: Closed
The purpose of this global study is to provide evidence of the efficacy and safety of 210 mg dose of tezepelumab administered every 4 weeks subcutaneously in adults and adolescents (12 years of age and older) with a history of asthma exacerbations and severe uncontrolled asthma receiving medium or high dose inhaled corticosteroids plus at least one…